Goldenwell Biotech (GWLL) Common Equity (2019 - 2025)
Goldenwell Biotech filings provide 7 years of Common Equity readings, the most recent being -$94823.0 for Q3 2025.
- On a quarterly basis, Common Equity fell 592.87% to -$94823.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$94823.0, a 592.87% decrease, with the full-year FY2024 number at -$47241.0, down 155.76% from a year prior.
- Common Equity hit -$94823.0 in Q3 2025 for Goldenwell Biotech, down from -$86838.0 in the prior quarter.
- In the past five years, Common Equity ranged from a high of $372594.0 in Q1 2021 to a low of -$94823.0 in Q3 2025.
- Median Common Equity over the past 5 years was $140929.0 (2023), compared with a mean of $135183.3.
- Biggest five-year swings in Common Equity: skyrocketed 48.11% in 2021 and later plummeted 2369.68% in 2025.
- Goldenwell Biotech's Common Equity stood at $301713.0 in 2021, then crashed by 33.18% to $201618.0 in 2022, then tumbled by 57.98% to $84723.0 in 2023, then crashed by 155.76% to -$47241.0 in 2024, then crashed by 100.72% to -$94823.0 in 2025.
- The last three reported values for Common Equity were -$94823.0 (Q3 2025), -$86838.0 (Q2 2025), and -$81618.0 (Q1 2025) per Business Quant data.